Literature DB >> 7634590

The problem is osteolysis.

W H Harris1.   

Abstract

Recent studies have generated considerable information that reveals substantial support for major change in the understanding of total hip arthroplasty and its current state. Although some of these observations appear unrelated at first glance, they can be drawn together to support the thesis that osteolysis is the dominant problem in total hip arthroplasty. These observations are as follows: (1) Five-year followup data are required for a minimum assessment of a new concept in total hip design and material because osteolysis is uncommon before that time. (2) Excellent fixation can be achieved on the femoral side with good cementing and good cementless techniques. Thus, femoral component loosening is less of an issue currently. (3) Many acetabular components become loose because of the ingress of particulate debris that leads to linear bone loss at the interface with the pelvis, a process that is biologically akin to the more florid forms of osteolysis. Thus, much acetabular component loosening represents a form of osteolysis. (4) Many cementless femoral reconstructions have developed a high incidence of femoral osteolysis. (5) Many cementless sockets have developed a high incidence of pelvic osteolysis. Taken in conjunction, these observations suggest that periprosthetic osteolysis is the leading problem in contemporary total hip replacement.

Entities:  

Mesh:

Year:  1995        PMID: 7634590

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  96 in total

1.  Wear mode and wear mechanism of retrieved acetabular cups.

Authors:  Kengo Yamamoto; Atsuhiro Imakiire; Toshinori Masaoka; Takaaki Shishido; Tatsuro Mizoue; Ian C Clarke; Hiromu Shoji; Keiichi Kawanabe; Jiro Tamura
Journal:  Int Orthop       Date:  2003-06-21       Impact factor: 3.075

2.  Early aseptic loosening of cemented total hip arthroplasty: the influence of non-steroidal anti-inflammatory drugs and smoking.

Authors:  M H A Malik; J Gray; P R Kay
Journal:  Int Orthop       Date:  2004-03-27       Impact factor: 3.075

3.  Wear analysis of chamfered elongated acetabular cup liners.

Authors:  Hsiao-Che Lin; Tzuo-Liang Luo; Jian-Horng Chen
Journal:  Med Biol Eng Comput       Date:  2011-12-22       Impact factor: 2.602

4.  Second-generation annealed highly cross-linked polyethylene exhibits low wear.

Authors:  James A D'Antonio; William N Capello; Rama Ramakrishnan
Journal:  Clin Orthop Relat Res       Date:  2011-12-09       Impact factor: 4.176

5.  Hip painful prosthesis: surgical view.

Authors:  Antonio Spinarelli; Vittorio Patella; Vito Conserva; Giovanni Vicenti; Vito Pesce; Silvio Patella
Journal:  Clin Cases Miner Bone Metab       Date:  2011-05

6.  Periprosthetic bone density as outcome of therapeutic response.

Authors:  Giovanni Iolascon; Gioconda Di Pietro; Annarita Capaldo; Carmine Gioia; Salvatore Gatto; Francesca Gimigliano
Journal:  Clin Cases Miner Bone Metab       Date:  2010-01

7.  Is routine mid-term total hip arthroplasty surveillance beneficial?

Authors:  James A Keeney; Bradley S Ellison; William J Maloney; John C Clohisy
Journal:  Clin Orthop Relat Res       Date:  2012-06-06       Impact factor: 4.176

8.  Excellent results with cementless total hip arthroplasty and alumina-on-alumina pairing: minimum ten-year follow-up.

Authors:  Alexander M Kress; Rainer Schmidt; Ulrich Holzwarth; Raimund Forst; Lutz A Mueller
Journal:  Int Orthop       Date:  2010-11-16       Impact factor: 3.075

Review 9.  [Failure analysis of total knee replacement. Basics and methodological aspects of the damage analysis].

Authors:  R Bader; W Mittelmeier; E Steinhauser
Journal:  Orthopade       Date:  2006-09       Impact factor: 1.087

10.  Sirtuin 1 inhibits TNF-α-mediated osteoclastogenesis of bone marrow-derived macrophages through both ROS generation and TRPV1 activation.

Authors:  Shu Yan; Lujie Miao; Yahua Lu; Liangzhi Wang
Journal:  Mol Cell Biochem       Date:  2018-11-20       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.